logo-loader
viewAshmore Group

Ashmore downgraded by UBS

 

The emerging markets fund manager Ashmore (LON:ASH) has been downgraded by UBS on valuation grounds and tighter emerging market bond spreads. The bank has moved its recommendation to ‘neutral’ from ‘buy’, while the target price has also been shaved back – by 15 pence a share to 375 pence.

 

share_price_down350_50f9428f3c7c8.jpg

 

The emerging markets fund manager Ashmore (LON:ASH) has been downgraded by UBS on valuation grounds and tighter emerging market bond spreads.

The bank has moved its recommendation to ‘neutral’ from ‘buy’, while the target price has also been shaved back – by 15 pence a share to 375 pence.

At 12.30pm, the stock was off 3% at 354.9 pence.

In a note to clients, UBS said: “We have undertaken some detailed emerging market debt fund comparative analysis, and conclude that despite good performances in 2012 by Ashmore funds, the three- and five-year performance remains mixed, which could challenge the premium pricing.”


 

Quick facts: Ashmore Group

Price: 446.608 GBX

LSE:ASHM
Market: LSE
Market Cap: £3.18 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tiziana Life Sciences: Dr Weiner announces 'completely novel' approach to...

Harvard Medical School's Dr Howard Weiner, who's also chairman of Tiziana Life Sciences' (LON:TILS)(NASDAQ:TLSA) scientific advisory board, speaks to Proactive London's Andrew Scott after winning a competitive research grant from the NIH (National Institutes of Health) to investigate the drug's...

3 hours, 23 minutes ago

2 min read